Background-Outcomes for organ transplantation are constantly improving because of advances in organ preservation, surgical techniques, immune clinical monitoring, and immunosuppressive treatment preventing acute transplant rejection. However, chronic rejection including transplant vasculopathy still limits long-term patient survival. Transplant vasculopathy is characterized by progressive neointimal hyperplasia leading to arterial stenosis and ischemic failure of the allograft. This work sought to decipher the manner in which the humoral immune response, mimicked by W6/32 anti-HLA antibody, contributes to transplant vasculopathy. Methods and Results-Studies were performed in vitro on cultured human smooth muscle cells, ex vivo on human arterial segments, and in vivo in a model consisting of human arterial segments grafted into severe combined immunodeficiency/beige mice injected weekly with anti-HLA antibodies. We report that anti-HLA antibodies are mitogenic for smooth muscle cells through a signaling mechanism implicating matrix metalloproteinases (MMPs) (membrane type 1 MMP and MMP2) and neutral sphingomyelinase-2. This mitogenic signaling and subsequent DNA synthesis are blocked in smooth muscle cells silenced for MMP2 or for neutral sphingomyelinase-2 by small interfering RNAs, in smooth muscle cells transfected with a vector coding for a dominant-negative form of membrane type 1 MMP, and after treatment by pharmacological inhibitors of MMPs (Ro28-2653) or neutral sphingomyelinase-2 (GW4869). In vivo, Ro28-2653 and GW4869 reduced the intimal thickening induced by anti-HLA antibodies in human mesenteric arteries grafted into severe combined immunodeficiency/beige mice.
long-term allograft rejection and induce intimal proliferation of smooth muscle cells (SMCs), a key event in the genesis of transplant vasculopathy. 9 -12 Anti-HLA antibodies trigger the production of growth factors and inflammatory cytokines (fibroblast growth factor, interferon, tumor necrosis factor-␣ [TNF-␣]), the expression of antiapoptotic members of the Bcl-2 family, and activation of signaling pathways involved in the migration and proliferation of vascular cells. [11] [12] [13] [14] [15] Moreover, the proinflammatory environment elicited by immune system activation is able to dedifferentiate SMCs that acquire a synthetic phenotype and produce cytokines and extracellular matrix. 16 On the basis of the response of vascular cells to anti-HLA monoclonal antibody (mAb) W6/32 reported by Reed et al, [11] [12] [13] [14] we recently developed an original model of human mesenteric arteries grafted into severe combined immunodeficiency (SCID)/beige mice, in which passive transfer of W6/32 mAb toward HLA class I provokes transplant vasculopathy in the absence of cellular immunity. 17 The sphingomyelin/ceramide signaling pathway is involved in various stress-induced responses 18 and plays a role in the mitogenic response of vascular SMCs to TNF-␣, oxidized low-density lipoprotein, and H 2 O 2 . 19 -21 In this pathway, the activation of neutral sphingomyelinase-2 (nSMase2), which converts sphingomyelin into ceramide, requires the activation of the matrix metalloproteinases (MMPs) membrane type 1 MMP (MT1-MMP) and MMP2. 19, 20 Moreover, MMPs are involved in extracellular matrix degradation, cell migration, and proliferation 22, 23 and could be implicated in cardiac transplant vasculopathy and chronic allograft nephropathy. 24 -27 Because the precise mechanism of action of MMPs remains elusive, we hypothesized that MMPs and the sphingomyelin/ceramide pathways are activated by alloantibodies and thus contribute to the mitogenic signaling leading to intimal hyperplasia and vascular wall remodeling of human arteries grafted in SCID/beige mice. 17 This led us to investigate whether MMP and nSMase2 inhibitors may prevent alloantibody-induced SMC proliferation and transplant vasculopathy. This study was conducted in vitro in human cultured SMCs, ex vivo on human arterial segments, and in vivo on human arteries grafted into SCID/beige mice.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Cell Culture and Ex Vivo Experiments
Human mesenteric SMC primocultures were isolated from mesenteric arteries and characterized as described in the online-only Data Supplement. Human aortic SMCs (haSMC, CRL-1999 cell line) and murine aortic SMC (MOVAS, CRL-2797) were from ATCC (Manassas, VA). Cells were stimulated by W6/32 mAb, irrelevant mAb (IgG2a, same isotype as W6/32), or anti-mouse major histocompatibility complex mAb (28-14-8, recognizing H-2D b ), as reported in the online-only Data Supplement.
Ex vivo experiments were performed on human artery rings. After their recovery from mesenteric artery, the rings were immediately incubated in serum-free Dulbecco's modified Eagle's medium and stimulated by W6/32 mAb (1 g/mL) for 24 hours, in the presence or absence of pharmacological agents.
DNA Synthesis, Small Interfering RNA Targeting, and Cell Transfection
DNA synthesis was evaluated by [ 3 H]thymidine incorporation, as described. 28 Cell counting was performed with the use of a Z1 Beckman cell counter, as described in the online-only Data Supplement. SMC transfections by small interfering RNA (siRNA) targeting human nSMase2, MMP2, scrambled siRNA, or MT-E240A mutant vector coding for the catalytically inactive MT1-MMP (a generous gift from Dr Alex Strongin, La Jolla, CA) were done as reported. 20
Determination of MT1-MMP, MMP2, and nSMase2 Activities
MT1-MMP activity was determined in SMC extracts with the use of the MT1-MMP fluorogenic substrate dansyl-Pro-Leu-Ala-Cys(pOMeBz)-Trp-Ala-Arg-NH 2 . 29 MMP2 activity was determined in SMC supernatant and in the plasma from transplanted mice with the use of the MMP2 fluorogenic substrate MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH 2 . 29 The activity of nSMase2 was measured in SMC extracts with the use of radiolabeled sphingomyelin, as reported. 20
Human Mesenteric Arterial Segments Grafted Into SCID/Beige Mice
This experimental animal system has been characterized extensively, 30 -32 and its use with anti-HLA mAbs has been reported in a recent methodological article 17 and is briefly described in the online-only Data Supplement. The use of human mesentery from cadaveric organ donors was approved by the French Agence de Biomédecine and the Ethics Committee of the University Hospital of Toulouse. Experimental protocols on animals were conducted in accordance with the French legislation and the local ethical committee for animal experiments.
Histological Analysis and Histomorphometric Reconstitution of Arteries
Six weeks after transplantation, the mice were euthanized, and the grafted human arterial segments were removed, fixed, and embedded either in paraffin for histological analysis or in Tissue-Tek, and they were snap-frozen in liquid nitrogen for morphometric analysis. 17
Statistical Analyses
Data are presented as meanϮSD. Estimates of statistical significance were performed by t test or ANOVA followed by a multiple comparison procedure (with the use of SigmaStat 3.5, Systat software). In populations normally distributed and with equal variances, differences between mean values were evaluated by unpaired t test (2 groups) or by 1-way ANOVA (Ͼ2 groups). When a difference in the groups was detected by 1-way ANOVA, multiple comparisons (generally versus a control group) were performed by the Holm-Sidak test. Values of PϽ0.05 were considered significant. Figure III in the online-only Data Supplement), as reported. 33 Dose-response experiments (mitogenic effect of increasing W6/32 concentration) showed that 1 g/mL W6/32 mAb was optimal to trigger [ 3 H]thymidine incorporation in cultured SMCs ( Figure IVA in the online-only Data Supplement) and cell proliferation (increased cell number), as assessed by cell counting ( Figure IVB in the online-only Data Supplement). This W6/32 concentration (1 g/mL) exhibited no cytotoxic effect ( Figure IVC in the online-only Data Supplement) and was therefore utilized throughout the experiments (unless otherwise indicated). In contrast, the same concentration (1 g/mL) of an irrelevant mAb of the same isotype class as W6/32 (IgG2a) induced no mitogenic response ( Figure 1A) . Interestingly, the anti-mouse major histocompatibility complex 28-14-8 mAb triggered DNA synthesis in murine aortic SMCs (MOVAS, CRL-2797) but not in human SMCs, and, conversely, W6/32 mAb elicited no [ 3 H]thymidine incorporation in CRL-2797 ( Figure 1A ).
Results

Anti-HLA mAbs Trigger the Activation of MT1-MMP, MMP2, and nSMase2-Mediated Mitogenic Signaling in Human Cultured SMCs: Inhibition by MMP and nSMase2 Inhibitors
To exclude any activation resulting from Fc receptors or from the Fc portion of the anti-HLA mAb, we investigated the mitogenic effect of F(ab)Ј 2 fragments from the W6/32 mAb (kit Pierce F(ab)Ј 2 , Thermo Scientific). As shown in Figure 1B , both F(ab)Ј 2 fragments and intact mAb exhibited a similar mitogenic effect, indicating that [ 3 H]thymidine incorporation induced by W6/32 mAb is dependent on its anti-HLA specificity and independent of the Fc portion or of Fc receptors. These data are consistent with the lack of effect of irrelevant mAb.
Because several stress-inducing agents (eg, TNF-␣, oxidized low-density lipoprotein) trigger SMC proliferation via a signaling mechanism implicating the metalloproteinases MT1-MMP and MMP2 and the sphingolipid pathway, 19, 20 we investigated whether this signaling is involved in the W6/32 anti-HLA mAb-induced mitogenic effect. As shown in Figure  1C through 1H, mitogenic concentrations of W6/32 mAb activated MT1-MMP, MMP2, and nSMase in haSMCs (under the conditions used, no activation of acidic SMase was observed; data not shown). Interestingly, the activation of MMP2 and [ 3 H]thymidine incorporation by W6/32 mAb was inhibited by MMP2-specific siRNA and in haSMCs expressing dn-MT1, a dominant-negative form of MT1-MMP 20 ( Figure 1E and 1H). Moreover, nSMase2-specific siRNA abrogated the activation of nSMase2 and [ 3 H]thymidine incorporation by W6/32 mAb ( Figure 1G and 1H).
Altogether, these data suggest that the W6/32 anti-HLA mAb is mitogenic for human vascular SMCs via the activation of the MMP/nSMase2 signaling pathway. This led us to anticipate that pharmacological inhibitors of MMPs and nSMase2 should inhibit the mitogenic effect of W6/32 mAb.
We first investigated the relative efficacy of 2 MMP inhibitors: batimastat, a broad-spectrum MMP inhibitor, and Ro28-2653, which is more specific for MMP2 and MT1-MMP. 19 Dose-response experiments allowed selection of the nontoxic concentration effective to inhibit the mitogenic effect of W6/32 mAb (10 nmol/L for Ro28-2653 and 100 nmol/L for batimastat) (Figures V and VI in the online-only Data Supplement). The 2 MMP inhibitors efficiently inhibited the activation of MT1-MMP and MMP2 (Figure 2A and 2B), thereby confirming the results observed in MMP2-silenced haSMCs ( Figure 1 ). MMP inhibition by batimastat or by Ro28-2653 also blocked the activation of nSMase2 ( Figure  2C ) and [ 3 H]thymidine incorporation elicited by W6/32 anti-HLA mAb ( Figure 2D ).
We then tested the effect of the SMase inhibitor GW4869, 34 which efficiently blocked the activation of nSMase2 and [ 3 H]thymidine incorporation elicited by W6/32 mAb ( Figure  2C and 2D) (as observed in SMCs silenced for nSMase2 by siRNA). Note that GW4869 had no inhibitory effect on MT1-MMP and MMP2 activation by W6/32 mAb (data not shown). Likewise, batimastat, Ro28-2653, and GW4869 inhibited [ 3 H]thymidine incorporation elicited by W6/32 mAb in SMC primocultures prepared from human mesenteric arteries ( Figure 2D ).
Altogether, these data suggest that MT1-MMP and MMP2 are required for the activation of nSMase2 by the anti-HLA W6/32 mAb and its subsequent mitogenic signaling. This indicates that W6/32 anti-HLA mAbs behave like stressinducing agents and activate the stress-induced mitogenic response mediated by the MMP/sphingolipid pathway in SMCs, as shown previously with stress-inducing agents. 19 -21 Interestingly, pharmacological inhibitors of MMPs and nSMase2 effectively abrogated DNA synthesis mediated by W6/32 mAb.
Histological Study of Human Mesenteric Arterial Segments Grafted Into SCID/Beige Mice
As indicated above, HLA class I antigens recognized by W6/32 mAb were expressed in human mesenteric arteries utilized for xenotransplantation ( Figure III in the online-only Data Supplement). As expected, the endothelial cell lining was intensely stained by W6/32, whereas the media was moderately labeled by W6/32 mAb. After subtraction of the yellow autofluorescence of the arterial wall, the green fluorescence of the media strongly suggests that SMCs of the media express HLA class I antigens ( Figure III in the online-only Data Supplement).
Immunodeficient SCID/beige mice, grafted with human mesenteric artery segments, were injected weekly with W6/32 anti-HLA mAb (1 g mAb per 10 g body wt for 5 weeks), irrelevant mAb (same protocol as W6/32), or vehicle (phosphate-buffered saline) only. 17 Histological studies were performed on the grafted human mesenteric artery segments recovered at the end of the treatment. In mice injected with phosphate-buffered saline vehicle ("untreated") or irrelevant mAb, we observed neither major histological alteration nor thrombosis ( Figure 3A ). Human mesenteric arteries grafted into mice treated by W6/32 mAb for 5 weeks developed lesions of transplant vasculopathy, characterized by a dramatic intimal hyperplasia (Figure 3A) , as reported previously. 17 Mouse aortic segments taken near the graft did not exhibit any histological alteration, in particular no intimal thickening (Figure 3B ). This is consistent with the specificity of the W6/32 mAb for human HLA antigens but not for murine major histocompatibility complex antigens 35, 36 and is in agreement with the lack of effect of W6/32 anti-HLA mAb on mouse SMCs ( Figure 1A ). Neointimal thickening of human arterial segments grafted in SCID/beige mice treated with W6/32 anti-HLA mAb is constituted by smooth muscle ␣-actin-positive cells (Figure 3C) and by collagen-rich extracellular matrix, colored blue by Masson trichrome staining ( Figure 3D ), similar to that observed in transplant vasculopathy. The tunica media of the grafted artery (treated or not with W6/32 mAb) was apparently not altered (Figure 3 ), thereby confirming that these antibodies are not cytotoxic and that intimal thickening may occur independently of media alteration. No inflammatory infiltration by lymphocytes and macrophages was detected in human mesenteric arteries before and after the vessels were grafted into SCID/beige mice (data not shown).
W6/32 Anti-HLA mAbs Induce MMP2 Expression, Mitogenic Signaling, and Intimal Thickening in Human Arterial Segments Transplanted Into SCID/Beige Mice: Prevention by Ro28-2653 and GW4869
Increased MMP2 expression was observed in the neointima of grafted human arterial segments ( Figure 4A and 4B ), in agreement with in vitro and ex vivo data and with a previous observation by Tsukioka et al 25 in a model of cardiac transplantation. Altogether, these data suggest that W6/32 anti-HLA mAbs enhance MMP2 expression in grafted arterial segments. Ro28-2653 prevented the rise in MMP2 expression in grafted human mesenteric segments ( Figure 4) . The experimental animal model (SCID/beige mice grafted with human mesenteric arteries and treated with W6/32) 17 was used to evaluate the in vivo efficacy of MMP and nSMase inhibitors in preventing intimal hyperplasia.
The mitogenic marker proliferating cell nuclear antigen (PCNA) was significantly increased in the intima and in the media of human arterial segments grafted in mice treated with anti-HLA mAb ( Figure 5A and 5B), consistent with cell proliferation leading to neointimal thickening and indicating that some SMCs are activated in the tunica media. The MMP inhibitor Ro28-2653 and nSMase2 inhibitor GW4869 prevented, in part, the increased PCNA expression induced by W6/32 anti-HLA mAb ( Figure 5A and 5B).
Morphometric analyses of serial histological sections allowed us to reconstruct the 3-dimensional details of the arterial wall ( Figure 6A ). This clearly shows the dramatic neointimal thickening of the human artery grafted in mice treated with W6/32 anti-HLA mAb. Interestingly, the MMP inhibitor Ro28-2653 and nSMase2 inhibitor GW4869 blocked the W6/32-induced neointimal thickening of the grafted arterial segments ( Figure 6A and 6B) .
In summary, our data show that, in this experimental model system, both MMP and nSMase2 inhibitors prevent the neointimal thickening occurring in vivo in grafted human arterial segments treated with anti-HLA mAb. The data support a role for MMP2 and nSMase2 in the pathogenesis of transplant vasculopathy and demonstrate the efficacy of these pharmacological inhibitors for preventing this severe complication.
Discussion
The innate and adaptive immune systems are thought to play a role in transplant vasculopathy, but the pathophysiological mechanism of arterial wall alteration remains unclear, and conventional immunosuppression is poorly effective in pre- venting transplant vasculopathy. 9 -11 HLA alloantibodies have been implicated in chronic allograft rejection and vascular cell proliferation, [13] [14] [15] 17 but thus far their mechanism of action is only partly understood. [13] [14] [15] The rationale of this study came from our previous work on the stress-induced sphingomyelin/ceramide pathway, which indicated a role for MMPs (namely, MT1-MMP and MMP2) and nSMase2 in stress-induced SMC proliferation. 19, 20 We hypothesized that this signaling may also be triggered by anti-HLA mAbs, which behave like stress-inducing agents. Our results show that W6/32 anti-HLA mAb activates the MMP/nSMase2dependent pathway that is involved in DNA synthesis and in intimal hyperplasia. Moreover, the hypothesis is also supported by the protective effect of MMP and nSMase2 inhibitors Ro28-2653 and GW4869, which prevent the neointimal thickening of human arterial segments induced by W6/32 mAb.
The first striking result is that HLA humoral immunity (mimicked by W6/32 anti-HLA mAb stimulation) leads to SMC proliferation in vitro and is sufficient for inducing neointimal hyperplasia through the activation of MMP2 and nSMase2. The implication of MMPs in transplant vasculopathy development is often correlated with vascular remodeling occurring during neointimal proliferation. 26 -28,37 Moreover, the concomitant inhibition of anti-HLA mAb-induced MMP2 activation, mitogenic signaling, SMC proliferation, and neointimal hyperplasia by the MMP inhibitor Ro28-2653 is consistent with recent observational studies from Lutz et al, 24 Tsukioka et al, 25 and Hariya et al, 26 suggesting a strong association between MMP2 and transplant vasculopathy. These data and reports from Reed et al [11] [12] [13] [14] 35 indicate that multiple signaling pathways act together to trigger the mitogenic effect mediated by W6/32 mAbs. Note that the anti-HLA mAb concentration used in our experiments for triggering SMC proliferation was lower than that used by Reed, 35 but the dose-response curve showed that the W6/32 mAb concentration used here induces a proliferation in SMCs similar to that obtained with higher dose ( Figure IV in the online-only Data Supplement). In addition, differences in the cell type (SMCs versus endothelial cells) may also play a role because, in our experience, the stress-induced mitogenic response is higher in SMCs than in endothelial cells.
A major outcome is the efficacy of MMP inhibitors to reduce the neointimal thickening induced by anti-HLA mAb. This suggests that, in addition to other previously identified mitogenic pathways, MMP2 (and other MMPs targeted by Ro28-2653) plays a crucial role not only in cultured SMCs stimulated by various stress agents 19, 20 but also in vivo in the progression of transplant vasculopathy. MMP inhibitors tested in clinical trials for vascular diseases and cancer therapy exhibit nonnegligible toxicity, possibly because of their broad spectrum of activity. 38, 39 However, the MMP inhibitor Ro28-2653 is more specific and acts mainly on MMP2, MMP9, and MT1-MMP. This agent fits well with the specificity required for inhibiting the MMP/sphingolipid pathway and could be less toxic because of its relatively narrow specificity. 39 Moreover, it is of interest to inhibit both MMP2 and MMP9, which share various biological properties and could play a role in transplant vasculopathy. 40 Finally, this compound was easily administered to mice and was nontoxic over the treatment period.
Another important result is the demonstration that nSMase2 is implicated in SMC proliferation elicited by anti-HLA mAb. In agreement with our previous reports, 19, 20 nSMase2 activation requires MMP2 and MT1-MMP, as assessed by the inhibitory effect of MMP inhibitors, siRNA directed to MMP2, or overexpression of an inactive form of MT1-MMP (which acts in our system as a dominant-negative form 20 ). The precise molecular mechanisms by which MT1-MMP and MMP2 mediate the activation of nSMase2 on stimulation by anti-HLA mAb and subsequently the mitogenic signaling involved in transplant hyperplasia are not known. One hypothesis is that MMP2 and MT1-MMP form a complex at the plasma membrane, as suggested by Strongin, 41 which in turn may activate nSMase2 and sphingosine kinase-1, which finally generates sphingosine-1 phosphate (S1P). 19, 20 The specific implication of nSMase2 in SMC proliferation is supported by the inhibition of DNA synthesis by GW4869 (a specific nSMase inhibitor) or by nSMase2-specific siRNA. Interestingly, GW4869 significantly reduced the progression of transplant vasculopathy induced by W6/32 injection in SCID/beige mice grafted with human mesenteric arteries, confirming the role of nSMase2 and of the sphingolipid pathway in the pathophysiology of transplant vasculopathy. Our data demonstrate that the sphingolipid pathway is involved in the vascular response triggered by W6/32 HLA mAb in human arterial segments grafted in immunodeficient SCID/beige mice. Although there are thus far no known links directly connecting nSMase2 and sphingosine kinase-1, it is likely that S1P is involved in W6/32-induced intimal hyperplasia because S1P is able to mediate SMC migration and proliferation. 28, 42 Moreover, the role of S1P in transplant vasculopathy has been reported on the basis of the inhibitory effect on transplant rejection of FTY720, a structural analog of S1P that targets the S1P receptor S1P1 and acts as an immunosuppressor. 43 The role of this pathway in our model system is currently under investigation.
A number of articles have highlighted the role of inflammatory cytokines such as TNF-␣ and interferon-␥ in transplant vasculopathy. 2, 44, 45 This has been investigated by Tellides 44, 45 in SCID/beige mice grafted with human artery segments and "humanized" by injection of peripheral blood mononuclear cells allogeneic to the artery donor. 44 Because interferon-␥ is mainly produced by CD4 positive T-helper lymphocytes, 44, 45 a role of interferon-␥ is a priori unlikely in our model, which only explores the humoral response. However, anti-HLA mAb may induce the expression and secretion of various inflammatory factors and cytokines including TNF-␣, which activates nSMase2 and formation of sphingo-lipid mediators. 18, 20 Interestingly, TNF-␣ induces SMC proliferation dependent on the MMP/nSMase2 signaling, which is inhibited by MMP inhibitors. 20 In the local inflammatory context of transplant vasculopathy, inflammatory cytokines might contribute to the mitogenic signaling mediated by anti-HLA mAb via the MMP/nSMase2 pathway, and their mitogenic effect could be inhibited by MMP and/or nSMase2 inhibitors.
In conclusion, we show that W6/32 anti-HLA mAb triggers SMC proliferation and neointimal hyperplasia, independently of any cellular immune response. This is in agreement with clinical observations suggesting that B cells and donor-specific antibodies can induce neointimal hyperplasia and transplant vasculopathy in animal models 5, 7, 8 and compromise long-term allograft survival. [25] [26] [27] Our data emphasize the critical role of the stressinduced MMP/sphingolipid pathway in the mitogenic signaling and the efficacy of MMP and nSMase2 inhibitors (Ro28-2653 and GW4869). In addition to classic immunosuppression, these agents could constitute a supplementary treatment for preventing transplant vasculopathy by reducing the response of vascular cells to alloantibody-induced stress. Figure 6 . Ro28-2653 and GW4869 prevent neointimal thickening in human mesenteric segments grafted into severe combined immunodeficiency/beige mice treated by W6/32 monoclonal antibody (mAb). A, Intimal thickening of human mesenteric arteries grafted in severe combined immunodeficiency/beige immunodeficient mice, treated with irrelevant mAb (negative control) or W6/32 mAb (anti-HLA) and with or without Ro28-2653 or GW4869, under the conditions of Figure 5 . Histological serial sections were stained, and intimal hyperplasia was estimated by histomorphological analysis. Top, Representative histological sections, with the neointimal area colorized pink (false color making easier the histomorphological evaluation), whereas media and adventitia are colored blue. Measurements of intimal thickening were made every 200 m along the length of the grafted artery (Ϸ8 mm long). Bottom, Serial histomorphometric analysis allowed reconstruction of a schematic representation of the vascular wall (blue) and intimal thickening (pink) of the grafted human mesenteric arteries (mean values of at least 5 experiments). B, Evaluation of the neointimal thickening (intimal hyperplasia) of the grafted arteries from control (untreated) mice (nϭ12), mice treated with irrelevant antibodies (I) (nϭ5), and mice treated with W6/32 mAb (H) (nϭ14), W6/32 mAb plus Ro28-2653 (H/Ro) (nϭ7), and W6/32 mAb plus GW4869 (H/GW) (nϭ5). Intimal hyperplasia was evaluated by the neointimal index, according to Galvani et al. 17 The data are expressed as meanϮSD and analyzed by 1-way ANOVA and pairwise multiple comparisons by Holm-Sidak method. *PϽ0.05.
